Two Sigma Advisers’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14M | Buy |
4,070,300
+1,425,500
| +54% | +$4.89M | 0.03% | 421 |
|
|
2025
Q1 | $5.9M | Buy |
2,644,800
+36,400
| +1% | +$81.2K | 0.01% | 720 |
|
|
2024
Q4 | $7.64M | Buy |
2,608,400
+430,800
| +20% | +$1.26M | 0.02% | 559 |
|
|
2024
Q3 | $5.66M | Buy |
2,177,600
+412,800
| +23% | +$1.07M | 0.01% | 669 |
|
|
2024
Q2 | $5.22M | Buy |
1,764,800
+7,200
| +0.4% | +$21.3K | 0.01% | 740 |
|
|
2024
Q1 | $7.96M | Buy |
1,757,600
+764,300
| +77% | +$3.46M | 0.02% | 607 |
|
|
2023
Q4 | $5.67M | Buy |
993,300
+290,400
| +41% | +$1.66M | 0.01% | 749 |
|
|
2023
Q3 | $3.23M | Buy |
702,900
+112,600
| +19% | +$518K | 0.01% | 938 |
|
|
2023
Q2 | $3.81M | Buy |
590,300
+49,900
| +9% | +$322K | 0.01% | 880 |
|
|
2023
Q1 | $4.07M | Sell |
540,400
-88,400
| -14% | -$667K | 0.01% | 897 |
|
|
2022
Q4 | $6.37M | Buy |
628,800
+161,100
| +34% | +$1.63M | 0.02% | 680 |
|
|
2022
Q3 | $4.63M | Buy |
467,700
+420,400
| +889% | +$4.16M | 0.01% | 771 |
|
|
2022
Q2 | $504K | Buy |
47,300
+22,900
| +94% | +$244K | ﹤0.01% | 1919 |
|
|
2022
Q1 | $238K | Buy |
+24,400
| New | +$238K | ﹤0.01% | 2327 |
|
|
2021
Q2 | – | Sell |
-20,800
| Closed | -$706K | – | 2419 |
|
|
2021
Q1 | $706K | Buy |
+20,800
| New | +$706K | ﹤0.01% | 1845 |
|